Speaker
Description
Breast cancer, the most common cancer worldwide, is a malignant type known for its high potential to metastasize to the brain, lungs and liver. Bleomycin (BLM) is an antineoplastic drug belonging to the glycopeptide antibiotic group which cannot cross the blood-brain barrier (BBB). This study uniquely investigates the effect of Bleomycin treatment on seizures in breast cancer animal models and how this effect changes in relation to RF exposure.The results indicate that c-Fos expression varied across treatment groups, with weak staining in the control groups and increased expression with longer treatment durations. The 30-day RF group showed a moderate c-Fos reaction, suggesting that RF exposure may enhance cellular stress responses, increasing c-Fos expression. The 30-day Bleomycin group showed a more pronounced reaction compared to the 7-day group, highlighting the cumulative effect of prolonged Bleomycin treatment. The RF+Bleomycin combination, especially in the 30-day group, showed a synergistic effect, with c-Fos expression increasing from weak to moderate, suggesting potential interactions between the treatments. These findings emphasize the need for further investigation into the combined effects of RF and Bleomycin in cancer therapy.
